Acrodermatitis chronica atrophicans: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 22: Line 22:
'''Acrodermatitis chronica atrophicans''' (ACA) is a [[skin rash]] indicative of the third or late stage of European [[Lyme Disease|Lyme borreliosis]].  
'''Acrodermatitis chronica atrophicans''' (ACA) is a [[skin rash]] indicative of the third or late stage of European [[Lyme Disease|Lyme borreliosis]].  


ACA is a [[dermatology|dermatological]] condition that takes a chronically progressive course and finally leads to a widespread [[atrophy]] of the skin. Involvement of the [[peripheral nervous system]] is often observed, specifically [[polyneuropathy]].
ACA is a [[dermatology|dermatological]] condition that takes a chronically progressive course and finally leads to a widespread [[atrophy]] of the skin. Involvement of the [[peripheral nervous system]] is often observed, specifically [[polyneuropathy]].


This progressive skin process is due to the effect of continuing active infection with the [[spirochete]] [[Lyme disease microbiology|Borrelia afzelii]]. B afzelii is the predominant pathophysiology, but may not be the exclusive, [[etiology|etiologic]] agent of ACA. Borrelia garinii, has also been detected.
This progressive skin process is due to the effect of continuing active infection with the [[spirochete]] [[Lyme disease microbiology|Borrelia afzelii]]. B afzelii is the predominant pathophysiology, but may not be the exclusive, [[etiology|etiologic]] agent of ACA. Borrelia garinii, has also been detected.


==History==
==Historical Perspective==
The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it.  
The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it.  


Line 53: Line 53:


{{Diseases of the skin and subcutaneous tissue}}
{{Diseases of the skin and subcutaneous tissue}}
{{SIB}}


[[Category:Disease]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Symptoms]]
[[Category:Symptoms]]
Line 62: Line 62:
[[Category:Spirochaetes]]
[[Category:Spirochaetes]]
[[Category:Infectious disease|*]]
[[Category:Infectious disease|*]]
[[Category:Ddx]]
 
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 04:53, 1 August 2012

Acrodermatitis chronica atrophicans
ICD-10 L90.4
ICD-9 701.8
DiseasesDB 32940

WikiDoc Resources for Acrodermatitis chronica atrophicans

Articles

Most recent articles on Acrodermatitis chronica atrophicans

Most cited articles on Acrodermatitis chronica atrophicans

Review articles on Acrodermatitis chronica atrophicans

Articles on Acrodermatitis chronica atrophicans in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acrodermatitis chronica atrophicans

Images of Acrodermatitis chronica atrophicans

Photos of Acrodermatitis chronica atrophicans

Podcasts & MP3s on Acrodermatitis chronica atrophicans

Videos on Acrodermatitis chronica atrophicans

Evidence Based Medicine

Cochrane Collaboration on Acrodermatitis chronica atrophicans

Bandolier on Acrodermatitis chronica atrophicans

TRIP on Acrodermatitis chronica atrophicans

Clinical Trials

Ongoing Trials on Acrodermatitis chronica atrophicans at Clinical Trials.gov

Trial results on Acrodermatitis chronica atrophicans

Clinical Trials on Acrodermatitis chronica atrophicans at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acrodermatitis chronica atrophicans

NICE Guidance on Acrodermatitis chronica atrophicans

NHS PRODIGY Guidance

FDA on Acrodermatitis chronica atrophicans

CDC on Acrodermatitis chronica atrophicans

Books

Books on Acrodermatitis chronica atrophicans

News

Acrodermatitis chronica atrophicans in the news

Be alerted to news on Acrodermatitis chronica atrophicans

News trends on Acrodermatitis chronica atrophicans

Commentary

Blogs on Acrodermatitis chronica atrophicans

Definitions

Definitions of Acrodermatitis chronica atrophicans

Patient Resources / Community

Patient resources on Acrodermatitis chronica atrophicans

Discussion groups on Acrodermatitis chronica atrophicans

Patient Handouts on Acrodermatitis chronica atrophicans

Directions to Hospitals Treating Acrodermatitis chronica atrophicans

Risk calculators and risk factors for Acrodermatitis chronica atrophicans

Healthcare Provider Resources

Symptoms of Acrodermatitis chronica atrophicans

Causes & Risk Factors for Acrodermatitis chronica atrophicans

Diagnostic studies for Acrodermatitis chronica atrophicans

Treatment of Acrodermatitis chronica atrophicans

Continuing Medical Education (CME)

CME Programs on Acrodermatitis chronica atrophicans

International

Acrodermatitis chronica atrophicans en Espanol

Acrodermatitis chronica atrophicans en Francais

Business

Acrodermatitis chronica atrophicans in the Marketplace

Patents on Acrodermatitis chronica atrophicans

Experimental / Informatics

List of terms related to Acrodermatitis chronica atrophicans

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Synonyms and keywords: Pick-Herxheimer disease

Overview

Acrodermatitis chronica atrophicans (ACA) is a skin rash indicative of the third or late stage of European Lyme borreliosis.

ACA is a dermatological condition that takes a chronically progressive course and finally leads to a widespread atrophy of the skin. Involvement of the peripheral nervous system is often observed, specifically polyneuropathy.

This progressive skin process is due to the effect of continuing active infection with the spirochete Borrelia afzelii. B afzelii is the predominant pathophysiology, but may not be the exclusive, etiologic agent of ACA. Borrelia garinii, has also been detected.

Historical Perspective

The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it.

Herxheimer and Hartmann described it in 1902 as a "tissue paper" like cutaneous atrophy.

Presentation

The rash caused by ACA is most evident on the extremities or limbs beginning with an inflammatory stage with bluish red discoloration and cutaneous swelling and concluding several months or years later with an atrophic phase. Sclerotic skin plaques may also develop.

As ACA progresses the skin begins to wrinkle.

Prognosis and Treatment

The course of ACA is long-standing, from a few to several years, and it leads to extensive atrophy of the skin and, in some patients, to the limitation of upper and lower limb joint mobility.

The outlook is good if the acute inflammatory stage of ACA is treated adequately. The therapeutic outcome is difficult to assess in patients with the chronic atrophic phase, in which many changes are only partially reversible.

Physicians should use serologic and histologic examination to confirm the diagnosis of ACA. Treatment consists of antibiotics including doxycycline and penicillin for up to four weeks in the acute case.

See also

External links


Template:WikiDoc Sources